Oric Pharmaceuticals, Inc. (ORIC) Institutional Ownership

Ownership Summary

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) appears in 162 institutional 13F filings for the quarter ending December 2025.

• Their combined ownership stood at 118.1% of outstanding shares in December 2025, up from 108.9% in September 2025.
• Their total shares held in ORIC increased 12.55% quarter over quarter, and separately, investors owning Oric Pharmaceuticals increased 25.58% from a year ago.
• Activity in ORIC broke down as 103 buyers, 34 sellers, and 25 unchanged among 162 total holders.
• Altogether, these fund groups held 116.88Mn shares in ORIC by December 2025, up by 13.03Mn shares quarter on quarter, and up 40.67Mn shares year over year.
• Nextech Invest, Ltd. holds the largest position in ORIC at 7.16Mn shares as of December 31, 2025, or 7.24% of shares outstanding.
• The biggest buyers of Oric Pharmaceuticals for the quarter ending December 2025 included Paradigm Biocapital Advisors LP (2.4Mn), State Street Corp (1.85Mn), CITADEL ADVISORS LLC (1.24Mn), Qube Research & Technologies Ltd (1.21Mn), Goldman Sachs Group Inc (1.03Mn).
• Top sellers of ORIC stock for the quarter ending December 2025 included Jpmorgan Chase & Co (2.04Mn), Vivo Capital, LLC (1.01Mn), VR Adviser, LLC (920.66K), SILVERARC CAPITAL MANAGEMENT, LLC (832.2K), BALYASNY ASSET MANAGEMENT L.P. (569.1K).
• According to Business Quant data, leading holders of ORIC for December 2025 are Nextech Invest, Ltd. (7.16Mn), EcoR1 Capital, LLC (6.73Mn), VIKING GLOBAL INVESTORS LP (6.57Mn), BlackRock, Inc. (5.87Mn), VR Adviser, LLC (5.68Mn), Pfizer Inc (5.38Mn), VANGUARD GROUP INC (4.54Mn), SR ONE CAPITAL MANAGEMENT, LP (4.51Mn), ALKEON CAPITAL MANAGEMENT LLC (4.5Mn), State Street Corp (4.26Mn).